1. patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). 2. patients with serious liver disease (increase of liver transaminases enzymes). 3. patients with severe renal impairment (denoted by increase serum urea \& serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. patients with severe anemia. 5. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. 6. patients with a history of allergy to medications or its metabolic components. 7. patients who have not signed informed consent. 8. patients participating in other clinical trials for covid-19 within 30 days prior to screening. 9. patients participating in other clinical research in the past three months.

1. patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). 2. patients with serious liver disease (increase of liver transaminases enzymes). 3. patients with severe renal impairment (denoted by increase serum urea \& serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. patients with severe anemia. 5. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. 6. patients with a history of allergy to medications or its metabolic components. 7. patients who have not signed informed consent. 8. patients participating in other clinical trials for covid-19 within 30 days prior to screening. 9. patients participating in other clinical research in the past three months.

patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). patients with serious liver disease (increase of liver transaminases enzymes). patients with severe renal impairment (denoted by increase serum urea & serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. patients with severe anemia. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. patients with a history of allergy to medications or its metabolic components. patients who have not signed informed consent. patients participating in other clinical trials for covid-19 within 30 days prior to screening. patients participating in other clinical research in the past three months.

patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). patients with serious liver disease (increase of liver transaminases enzymes). patients with severe renal impairment (denoted by increase serum urea & serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. patients with severe anemia. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. patients with a history of allergy to medications or its metabolic components. patients who have not signed informed consent. patients participating in other clinical trials for covid-19 within 30 days prior to screening. patients participating in other clinical research in the past three months.

1. patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). 2. patients with serious liver disease (increase of liver transaminases enzymes). 3. patients with severe renal impairment (denoted by increase serum urea & serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. patients with severe anemia. 5. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. 6. patients with a history of allergy to medications or its metabolic components. 7. patients who have not signed informed consent. 8. patients participating in other clinical trials for covid-19 within 30 days prior to screening. 9. patients participating in other clinical research in the past three months.

1. patients who are unsuitable or who cannot participate safely in the study, as judged by the principal investigator (pi). 2. patients with serious liver disease (increase of liver transaminases enzymes). 3. patients with severe renal impairment (denoted by increase serum urea & serum creatinine) or continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. patients with severe anemia. 5. women with a positive pregnancy test, ongoing pregnancy, or who are breastfeeding. 6. patients with a history of allergy to medications or its metabolic components. 7. patients who have not signed informed consent. 8. patients participating in other clinical trials for covid-19 within 30 days prior to screening. 9. patients participating in other clinical research in the past three months.